Neuropeptide action can be terminated by proteolytic inactivation. In some cases the products of neuropeptide degradation can also have biological activity (biotransformation). We and others have recently obtained evidence to support the hypothesis that part or all of the biological activity of the brain renin-angiotensin (ang) system is mediated by the ang II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) metabolite ang III (des Asp-ang II). The conversion of ang II to and III is catalyzed by two acidic amino acid proferring aminopeptidases. In addition to the well known enzyme isolated rabbit brain and termed aspartyl aminopeptides (D-AP). Its substrates can include angiotensins I and II, cholecystokinin-8, and neuropeptide K. The sole produce of the action of D-AP on ang II is and III. The specificity constant (kcat/Km) of ang II is similar with both enzymes. We obtained sequences of three tryptic peptides from the purified rabbit brain enzyme and located these sequences within the expressed sequence tag data base. Full length human and mouse cDNA's were found and the human enzyme expressed. Aspartyl aminopeptidase is the first mammalian member of the M18 family of metalloproteinases, and has been assigned to chromosome 2q. It is an abundant ezyme (0.1% of brain soluble protein) and its sequence is highly conserved. Levels of D-AP were reported to be lowered in the frontal cortex of aged rats. To explore the physiological significance of brain D-AP, we propose characterization of its mechanism of action by site-directed mutagenesis, studies on the relationship of subunit structure to activity, determination of its localization, synthesis and evaluation of new thiol containing inhibitors and identification of endogenous interacting proteins.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS017392-19
Application #
6330407
Study Section
Special Emphasis Panel (ZRG1-MDCN-5 (01))
Program Officer
Mitler, Merrill
Project Start
1981-07-01
Project End
2003-11-30
Budget Start
2000-12-01
Budget End
2003-11-30
Support Year
19
Fiscal Year
2001
Total Cost
$296,028
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Pharmacology
Type
Schools of Medicine
DUNS #
114400633
City
New York
State
NY
Country
United States
Zip Code
10029
Shane, R; Wilk, S; Bodnar, R J (1999) Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV. Brain Res 815:278-86
Papandreou, C N; Usmani, B; Geng, Y et al. (1998) Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 4:50-7
Lin, J; Wilk, S (1998) Quantitation and regulation of pyroglutamyl peptidase II messenger RNA levels in rat tissues and GH3 cells. Neuroendocrinology 67:197-208
Wilk, S; Wilk, E; Magnusson, R P (1998) Purification, characterization, and cloning of a cytosolic aspartyl aminopeptidase. J Biol Chem 273:15961-70
Jiang, J D; Wilk, S; Li, J et al. (1997) Inhibition of human immunodeficiency virus type 1 infection in a T-cell line (CEM) by new dipeptidyl-peptidase IV (CD26) inhibitors. Res Virol 148:255-66
Song, L; Wilk, S; Healy, D P (1997) Aminopeptidase A antiserum inhibits intracerebroventricular angiotensin II-induced dipsogenic and pressor responses. Brain Res 744:1-6
Li, J; Wilk, E; Wilk, S (1996) Inhibition of prolyl oligopeptidase by Fmoc-aminoacylpyrrolidine-2-nitriles. J Neurochem 66:2105-12
Figueiredo-Pereira, M E; Chen, W E; Yuan, H M et al. (1995) A novel chymotrypsin-like component of the multicatalytic proteinase complex optimally active at acidic pH. Arch Biochem Biophys 317:69-78
Li, J; Wilk, E; Wilk, S (1995) Aminoacylpyrrolidine-2-nitriles: potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26). Arch Biochem Biophys 323:148-54
Song, L; Ye, M; Troyanovskaya, M et al. (1994) Rat kidney glutamyl aminopeptidase (aminopeptidase A): molecular identity and cellular localization. Am J Physiol 267:F546-57

Showing the most recent 10 out of 37 publications